Manatt Logo
Menu
  • Industries
    • Manatt Digital and Technology
    • Manatt Energy and Environmental
    • Manatt Entertainment
    • Manatt Financial Services
    • Manatt Health
    • Manatt Real Estate
    • Manatt Retail and Consumer Products
  • Services
    • Business Strategy and Consulting
      • Digital and Technology Consulting
      • Digital Health
      • Manatt Health
      • Manatt Housing Solutions
      • Manatt Real Estate Advisors
      • Manatt's Recovery Team
      • Name Image Likeness (NIL) in College Athletics
    • Corporate and Finance
      • Blockchain and Cryptocurrency
      • Cannabis and CBD
      • Capital Markets
      • Digital and Technology Transactions
      • Distressed Assets
      • Estate Planning and Personal Representation
      • Executive Compensation and Employee Benefits
      • Financial Services Transactions
      • Fintech
      • Games and Esports
      • Global Payments
      • Health Care Transactions
      • Hospitality and Leisure
      • Impact Investing and Community Development
      • Manatt Leasing
      • Mergers and Acquisitions
      • Music
      • Name Image Likeness (NIL) in College Athletics
      • Private Equity and Buyout
      • Real Estate Transactions and Finance
      • Special Purpose Acquisition Companies (SPACs)
      • Tax
      • Venture Capital / Emerging Companies
    • Government and Regulatory
      • Advertising, Marketing and Media
      • California State Government and Regulatory Policy and Government Contracts
      • Environment
      • Federal Government Affairs and Public Policy
      • Government Litigation and Administrative Law
      • Insurance
      • Investigations, Compliance and White Collar Defense
      • Land Use
      • Los Angeles Government and Land Use
      • Manatt Energy and Environmental
      • Manatt Health
      • Medical Technology and Life Sciences FDA Regulation
      • New York City Government, Policy and Government Contracts
      • New York State Government, Regulatory Policy and Government Contracts
    • Litigation
      • Advertising Litigation
      • Antitrust and Competition
      • Appellate
      • Bankruptcy
      • Capabilities to Serve Clients During COVID-19
      • Class Actions
      • Consumer Protection
      • Digital Media Litigation
      • Employment and Labor
      • Entertainment Litigation
      • Environmental Litigation
      • False Claims Act
      • Financial Services Litigation and Enforcement
      • Games and Esports
      • Government Litigation and Administrative Law
      • Health Care Litigation
      • Insurance
      • Intellectual Property Protection and Enforcement
      • Investigations, Compliance and White Collar Defense
      • Music
      • Privacy and Data Security
      • Private Wealth and Fiduciary Disputes
      • Real Estate Litigation
      • TCPA Compliance and Class Action Defense
      • Technology and Intellectual Property Litigation
      • Trademark and Copyright Litigation
      • Unmanned Aircraft
  • People
  • Insights
    • News
    • Articles
    • Webinars
    • Podcasts
    • Events and Engagements
    • Newsletters
    • White Papers
  • Hot Topics
    • Reproductive Health
    • Metaverse
    • Long-Term Care/Long-Term Services and Supports
    • Behavioral Health
    • Drivers of Health
    • Children's Health
    • COVID-19
    • State Privacy Legislative Updates
    • Medicaid Managed Care
  • About Us
    • About Manatt
    • Contact Us
    • Management
    • Diversity
    • Women's Initiative
    • Pro Bono
    • Capabilities to Serve Clients During COVID-19
    • Manatt for Entrepreneurs
    • Manatt on Health
  • Careers
  • Offices
  • Manatt on Health
  • Manatt for Entrepreneurs
  • Client Login
Manatt Logo
  • Industries
    • Manatt Digital and Technology
    • Manatt Energy and Environmental
    • Manatt Entertainment
    • Manatt Financial Services
    • Manatt Health
    • Manatt Real Estate
    • Manatt Retail and Consumer Products
  • Services
    • Business Strategy and Consulting
      • Digital and Technology Consulting
      • Digital Health
      • Manatt Health
      • Manatt Housing Solutions
      • Manatt Real Estate Advisors
      • Manatt's Recovery Team
      • Name Image Likeness (NIL) in College Athletics
    • Corporate and Finance
      • Blockchain and Cryptocurrency
      • Cannabis and CBD
      • Capital Markets
      • Digital and Technology Transactions
      • Distressed Assets
      • Estate Planning and Personal Representation
      • Executive Compensation and Employee Benefits
      • Financial Services Transactions
      • Fintech
      • Games and Esports
      • Global Payments
      • Health Care Transactions
      • Hospitality and Leisure
      • Impact Investing and Community Development
      • Manatt Leasing
      • Mergers and Acquisitions
      • Music
      • Name Image Likeness (NIL) in College Athletics
      • Private Equity and Buyout
      • Real Estate Transactions and Finance
      • Special Purpose Acquisition Companies (SPACs)
      • Tax
      • Venture Capital / Emerging Companies
    • Government and Regulatory
      • Advertising, Marketing and Media
      • California State Government and Regulatory Policy and Government Contracts
      • Environment
      • Federal Government Affairs and Public Policy
      • Government Litigation and Administrative Law
      • Insurance
      • Investigations, Compliance and White Collar Defense
      • Land Use
      • Los Angeles Government and Land Use
      • Manatt Energy and Environmental
      • Manatt Health
      • Medical Technology and Life Sciences FDA Regulation
      • New York City Government, Policy and Government Contracts
      • New York State Government, Regulatory Policy and Government Contracts
    • Litigation
      • Advertising Litigation
      • Antitrust and Competition
      • Appellate
      • Bankruptcy
      • Capabilities to Serve Clients During COVID-19
      • Class Actions
      • Consumer Protection
      • Digital Media Litigation
      • Employment and Labor
      • Entertainment Litigation
      • Environmental Litigation
      • False Claims Act
      • Financial Services Litigation and Enforcement
      • Games and Esports
      • Government Litigation and Administrative Law
      • Health Care Litigation
      • Insurance
      • Intellectual Property Protection and Enforcement
      • Investigations, Compliance and White Collar Defense
      • Music
      • Privacy and Data Security
      • Private Wealth and Fiduciary Disputes
      • Real Estate Litigation
      • TCPA Compliance and Class Action Defense
      • Technology and Intellectual Property Litigation
      • Trademark and Copyright Litigation
      • Unmanned Aircraft
  • People
  • Insights
    • News
    • Articles
    • Webinars
    • Podcasts
    • Events and Engagements
    • Newsletters
    • White Papers
  • Hot Topics
    • Reproductive Health
    • Metaverse
    • Long-Term Care/Long-Term Services and Supports
    • Behavioral Health
    • Drivers of Health
    • Children's Health
    • COVID-19
    • State Privacy Legislative Updates
    • Medicaid Managed Care
  • About Us
    • About Manatt
    • Contact Us
    • Management
    • Diversity
    • Women's Initiative
    • Pro Bono
    • Capabilities to Serve Clients During COVID-19
    • Manatt for Entrepreneurs
    • Manatt on Health
  • Careers
  • Offices
  • Manatt on Health
  • Manatt for Entrepreneurs
  • Client Login
  • Home
  • People
  • Ian Spatz
Language:
  • English
    • English
    • Spanish
    • Portuguese
Share:

Ian Spatz

National Advisor

Manatt Health
Contact
  • ispatz@manatt.com
  • Phone: 310.312.4339
  • Download vCard
  • San Francisco
Bar Admissions
  • Washington, D.C.
Education
  • New York University School of Law, J.D.

    Princeton University, Princeton School of Public and International Affairs, M.P.A.

    Brandeis University, B.A.

Industries
  • Manatt Health

Show Full Bio

  • Profile
  • Speaking Engagements
  • Memberships
  • Publications
Profile

Profile

Ian Spatz counsels clients on health reform efforts and issues affecting health care providers and insurers, pharmaceutical companies, the consuming public, and U.S. health care initiatives.

Ian’s practice areas include national health care policies and programs; pharmaceutical pricing, including as it relates to Medicare and Medicaid; intellectual property protection; and policies related to the U.S. Food and Drug Administration's regulation of the research, approval, manufacturing and marketing of medicines.

Prior to joining Manatt, Ian served 15 years in increasingly responsible positions at Merck & Company Inc. As Merck’s vice president for global health policy, he directed U.S. public policy and related public affairs activities and represented the company before Congress, the White House and the media. Ian is also the founder and principal of the policy consulting firm Rock Creek Policy Group.

While at Merck, Ian led the successful five-year campaign that helped to develop and gain enactment of the Medicare prescription drug benefit, providing millions of American elderly and persons with disabilities with drug insurance for the first time. He also promoted legislation to create a program of market exclusivity incentives for research on the pediatric uses of medicines. In addition, he guided company efforts in resolving an international trade dispute over the licensing of medicines in the developing world.

Before joining Merck, Ian served as legislative director for Sen. Frank Lautenberg (D-NJ). In that role, he directed the senator's legislative staff in developing and implementing legislative strategies, proposal drafting and floor action, including coordinating the passage of appropriations bills.

Ian is a member of the faculty of the University of Southern California’s Price School of Public Policy where he teaches courses in health economics and health law.

Speaking Engagements

Speaking Engagements

Panelist, “Did the IRA Kill that Drug?,” Endpoints at #JPM23 Conference, JP Morgan, San Francisco, CA, January 11, 2023.

Memberships

Memberships

Admitted to practice in Washington, D.C.

Publications

Publications

Quoted, “Medicare Will Pick Drugs For Negotiation Based On Gross Sales, Disadvantaging Highly-Rebated Products,” Pink Sheet, January 12, 2023.

Quoted, “The way Medicare will negotiate down prescription drug prices takes shape,” MarketWatch, January 11, 2023.

Quoted, “Experts talk IRA impacts as CMS announces it will publish first 10 drugs up for negotiation in September,” Endpoints News, January 11, 2023.

Quoted, “What pharma could gain — or lose — from the midterms,” PharmaVoice, November 7, 2022.

Quoted, “Pharma can't give up on Dems as it tries to weaken drug price law,” Axios, October 5, 2022.

Author, “Implementing The Drug Negotiation Provisions Of The IRA: Considerations For CMS,” Health Affairs, September 30, 2022.

Quoted, “FTC And PBMs: Support For Investigation Building But Outcome May Ultimately Disappoint Critics,” Pink Sheet, May 25, 2022.

Quoted, “Biden Wants Congress To Set Sights On Cutting Drug Prices,” Law360, August 12, 2021.

Quoted, “Beyond Aduhelm: OIG Review Will Put FDA’s Entire Accelerated Approval Program Under Microscope,” Pink Sheet, August 4, 2021.

Quoted, “Biden Executive Order Targets Competition to Lower Drug Prices,” MedPage Today, July 12, 2021.

Co-author, “What’s Ahead for Health Policy in 2021,” RamaOnHealthcare, February 3, 2021.

Author, “FDA Calls States’ Bluffs on Drug Importation,” Stat, February 18, 2020.

Author, “Rush to End Drug Rebates May Be Bad for Patients, Payers, and Pharma,” Stat, September 7, 2018.

Author, “IPAB RIP,” Health Affairs blog, February 22, 2018.

Co-author, “The Future of Essential Health Benefits,” Health Affairs blog, February 14, 2017.

Co-author, “Supporting Informed Decision-Making in the Health Insurance Marketplace: A Progress Report,” National Partnership for Women and Families, February 2015.

Co-author, “Five Megatrends Driving the Seismic Shift in Healthcare: How Should Pharma Respond to Succeed in a Transformed Market?” Manatt Health Solutions, July 2014.

Author, “Medicare Part D Proposed Rule: Where Did Things Go Wrong?” Health Affairs blog, March 6, 2014.

Co-author, “Specialty Pharmaceuticals,” Health Affairs, November 25, 2013.

Co-author, "Sequestration and Medicare: The Two Percent Solution?" BNA's Medicare Report, September 16, 2011.

Co-author, "The Proposed ACO Program: Issues for the Life Sciences Industry," BNA's Life Sciences Law & Industry Report, May 6, 2011.

Co-author, “Affordable Care Act Provisions in the 2011 Medicare Physician Fee Rule,” BNA’s Medicare Report, July 23, 2010.

Ian in the News

  • 07.12.21

    Spatz Quoted in MedPage Today on Biden’s Executive Order to Lower ...

    Ian Spatz was quoted in MedPage Today on President Biden’s executive order aimed at improving competition in the pr...

  • 11.16.20

    Spatz Quoted in CNN on Potential Health Policy Changes Under a Biden ...

    Manatt Health counsel Allison Orris and senior advisor Ian Spatz spoke with CNN about healthcare measures a Biden administration will likely ...

  • 08.06.20

    Spatz Quoted in WSJ Pro Venture Capital on Potential Impact of Recent ...

    Manatt Health senior advisor Ian Spatz spoke with WSJ Pro Venture Capital on President Trump’s recent decision to issue a series of ...

  • 07.31.19

    Trump Administration Unveils New Plan for Drug Imports

    Manatt’s Ian Spatz, a senior advisor with Manatt Health, spoke with Inside Health Policy on the Trump administration’s newly a...

Show More

Ian's Articles

  • 09.30.22

    Implementing the Drug Negotiation Provisions of the IRA: ...

    In an article for Health Affairs, Manatt Health Senior Advisor Ian Spatz provided considerations for the Centers for Medicare & Medicaid ...



  • 02.18.20

    FDA calls states’ bluffs on drug importation

    Manatt Health senior advisor Ian Spatz wrote an article for STAT on the Food and Drug Administration’s recently proposed regulation to ...



  • 09.07.18

    Rush to End Drug Rebates May Be Bad for Patients, Payers, and Pharma

    In health care circles, 21 words have rarely caused as much speculation as “Removal of Safe Harbor Protection for Rebates to Plans or PBMs ...



  • 02.22.18

    IPAB RIP

    I come to bury IPAB, not to praise it. Like Brutus and his co-conspirators wielding the knife against Julius Caesar, the budget deal Congress ...



Show More


Ian's Newsletters

  • 04.14.22

    CMS Aduhelm Decision: Precedent for Future Coverage or a One-Off?

    On April 7, the Centers for Medicare & Medicaid Services released its highly anticipated final National Coverage Determination (NCD) for ...

  • 12.08.21

    Build Back Better: All Eyes on the Senate

    On November 19, the House of Representatives passed the Build Back Better Act (BBB) (H.R. 5376) by a vote of 220–213.

  • 08.17.21

    Senate Lays Groundwork for Fall Health Care Negotiations Before ...

    Before leaving for its August recess, the Senate made progress on two major Biden Administration priorities by passing bipartisan infrastructure ...

  • 02.03.21

    What’s Ahead for Health Policy in 2021

    The Biden Administration is just two weeks old, and President Biden has already issued more than two dozen Executive Orders on racial justice, health ...

Show More


Ian's Events and Webinars

  • 08.23.22

    Preparing for Change: A Guide to the Inflation Reduction Act Drug ...

    The Inflation Reduction Act (IRA) will make arguably the most significant changes to U.S. prescription drug pricing regulations ever, but certainly ...



  • 03.09.22

    Levers of Change: Remapping the Health Care Landscape

    President Biden set an ambitious health care agenda in his campaign and maintained that focus as he took office. The Biden administration has ...



  • 11.17.20

    Post-Election: How Will the 2020 Election Results Impact Healthcare?

    Healthcare continues to be one of the key factors driving voters’ decisions in the upcoming elections. With the death of Supreme Court Justice ...



  • 08.27.20

    Drug Pricing Proposals, Policies, Pushback and Politics: What’s New, ...

    On July 24, President Trump signed four executive orders (EOs) designed to lower drug prices, adding new fuel to the already raging debate around ...



Show More
manatt-black

ATTORNEY ADVERTISING

pursuant to New York DR 2-101(f)

© 2023 Manatt, Phelps & Phillips, LLP.

All rights reserved 

 

  • Services
  • People
  • Insights
  • About Us
  • Careers
  • Offices & Contacts
  • Disclaimer
  • Privacy Statement

Share This Page

Your Information
Recipient's Information